This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shetty, S. Articles by Gibson, S. B. Search for Related Content PubMed PubMed Citation Articles by Shetty, S. Articles by Gibson, S. B.

Transcription Factor NF-B Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1

Shashirekha Shetty, Bonnie A. Graham, Jennifer G. Brown, Xiaojie Hu, Nicolette Vegh-Yarema, Gary Harding, James T. Paul, and Spencer B. Gibson^*

Manitoba Institute of Cell Biology, University of Manitoba, 675 McDermot Ave., Winnipeg, Manitoba R3E 0V9, Canada

Received 28 February 2005/ Accepted 26 March 2005

The transcription factor nuclear factor B (NF-B) regulates the expression of both antiapoptotic and proapoptotic genes. Death receptor 5 (DR5, TRAIL-R2) is a proapoptotic protein considered to be a potential target for cancer therapy, and its expression is mediated by NF-B. The mechanism of NF-B-induced DR5 expression is, however, unknown. Herein, we determined that etoposide-induced DR5 expression requires the first intronic region of the DR5 gene. Mutation of a putative NF-B binding site in this intron eliminates DR5 promoter activity, as do mutations in the p53 binding site in this region. Reduction in p53 expression also blocks p65 binding to the intronic region of the DR5 gene, indicating cooperation between p53 and p65 in DR5 expression. In contrast, the antiapoptotic stimulus, epidermal growth factor (EGF), fails to increase DR5 expression but effectively activates NF-B and induces p65 binding to the DR5 gene. EGF, however, induces the association of histone deacetylase 1 (HDAC1) with the DR5 gene, whereas etoposide treatment fails to induce this association. Indeed, HDAC inhibitors activate NF-B and p53 and upregulate DR5 expression. Blockage of DR5 activation decreased HDAC inhibitor-induced apoptosis, and a combination of HDAC inhibitors and TRAIL increased apoptosis. This provides a mechanism for regulating NF-B-mediated DR5 expression and could explain the differential roles NF-B plays in regulating apoptosis.

S.S. and B.A.G. contributed equally to this paper.

This article has been cited by other articles:

• Kandasamy, K., Kraft, A. S. (2008). Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Molecular Cancer Therapeutics 7: 1091-1100 [Abstract] [Full Text]  
• Lu, M., Xia, L., Hua, H., Jing, Y. (2008). Acetyl-Keto-{beta}-Boswellic Acid Induces Apoptosis through a Death Receptor 5-Mediated Pathway in Prostate Cancer Cells. Cancer Res. 68: 1180-1186 [Abstract] [Full Text]  
• Chen, S., Liu, X., Yue, P., Schonthal, A. H., Khuri, F. R., Sun, S.-Y. (2007). CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in Human Non Small-Cell Lung Cancer Cells. Mol. Pharmacol. 72: 1269-1279 [Abstract] [Full Text]  
• Higashitsuji, H., Higashitsuji, H., Masuda, T., Liu, Y., Itoh, K., Fujita, J. (2007). Enhanced Deacetylation of p53 by the Anti-apoptotic Protein HSCO in Association with Histone Deacetylase 1. J. Biol. Chem. 282: 13716-13725 [Abstract] [Full Text]  
• Baritaki, S., Huerta-Yepez, S., Sakai, T., Spandidos, D. A., Bonavida, B. (2007). Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1. Molecular Cancer Therapeutics 6: 1387-1399 [Abstract] [Full Text]  
• Vousden, K. H. (2006). Outcomes of p53 activation - spoilt for choice. J. Cell Sci. 119: 5015-5020 [Abstract] [Full Text]  
• Ricci, M. S., Zong, W.-X. (2006). Chemotherapeutic approaches for targeting cell death pathways.. The Oncologist 11: 342-357 [Abstract] [Full Text]